Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Pisansky

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
JCO Clinical Cancer Informatics|July 1, 2022
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415Rahul Khairnar, Lyudmila DeMora, Howard M Sandler, et al.
The Lancet. Oncology|October 15, 2018
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trialMack Roach, Jennifer Moughan, Colleen A F Lawton, et al.
Plos One|April 14, 2021
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415Rahul Khairnar, Stephanie L Pugh, Howard M Sandler, et al.
European Urology Focus|February 2, 2024
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202Kimberley S Mak, Molly Scannell Bryan, James J Dignam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup>C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate CancerHenan Zhang, Jacob J Orme, Feven Abraha, et al.
The New England Journal of Medicine|February 2, 2017
Radiation with or without Antiandrogen Therapy in Recurrent Prostate CancerWilliam U Shipley, Wendy Seiferheld, Himanshu R Lukka, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2020
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-AnalysisDaniel E Spratt, Shawn Malone, Soumyajit Roy, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2020
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate CancerWilliam A Hall, Eric Paulson, Brian J Davis, et al.
JCO Precision Oncology|July 8, 2026
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologySophia C Kamran, Monica Borges, Jeff Michalski, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
JCO Clinical Cancer Informatics|July 1, 2022
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415Rahul Khairnar, Lyudmila DeMora, Howard M Sandler, et al.
The Lancet. Oncology|October 15, 2018
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trialMack Roach, Jennifer Moughan, Colleen A F Lawton, et al.
Plos One|April 14, 2021
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415Rahul Khairnar, Stephanie L Pugh, Howard M Sandler, et al.
European Urology Focus|February 2, 2024
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202Kimberley S Mak, Molly Scannell Bryan, James J Dignam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup>C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate CancerHenan Zhang, Jacob J Orme, Feven Abraha, et al.
The New England Journal of Medicine|February 2, 2017
Radiation with or without Antiandrogen Therapy in Recurrent Prostate CancerWilliam U Shipley, Wendy Seiferheld, Himanshu R Lukka, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2020
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-AnalysisDaniel E Spratt, Shawn Malone, Soumyajit Roy, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2020
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate CancerWilliam A Hall, Eric Paulson, Brian J Davis, et al.
JCO Precision Oncology|July 8, 2026
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologySophia C Kamran, Monica Borges, Jeff Michalski, et al.
Pageof 14